2015 American Transplant Congress
Alemtuzumab in Elderly Renal Transplant Recipients Is Not Associated With a Poor Outcome
Imperial College Renal and Transplant Centre, Hammersmith Hospital, London, United Kingdom.
The use and choice of induction immunosuppression in elderly kidney recipients remains unresolved. Alemtuzumab has been associated with a higher risk of death and graft…2015 American Transplant Congress
Effect of Induction in Renal Transplant Recipients Aged 70 and Over
Transplantation, Montefiore Medical Center, Bronx, NY.
While there is a significant survival advantage to transplanting patients 70 years of age and older versus staying on dialysis, it is unclear whether sensitized…2015 American Transplant Congress
Efficacy, Safety and Pharmacokinetics of Once-Daily, MeltDose® Tacrolimus (Envarsus® XR) Versus Twice-Daily Tacrolimus (Prograf®) in De Novo Kidney Transplant Recipient Sub-Groups: A 2 Year Phase 3 Randomized, Double-Blind, Double-Dummy, Trial
Differences in tacrolimus (tac) metabolism are evident in certain populations; in particular, lower tac bioavailability has been shown in females and black kidney transplant recipients…2015 American Transplant Congress
Excellent Outcomes With Kidney Transplantation for Patients ≥70 Years of Age
BackgroundOur aim was to determine the outcomes following kidney transplantation in recipients ≥70 years of age at the time of transplantation.Materials and MethodsWe analyzed data…2015 American Transplant Congress
Elderly Transplant Recipients Have Improved Graft Survival
Background: The upper age limit to receive a kidney transplant has progressively risen, but the outcomes of elderly (ages > 70) transplant recipients remain understudied.…
- « Previous Page
- 1
- …
- 15
- 16
- 17